News
Avalyn seeks $300m from its IPO

Avalyn seeks $300m from its IPO

Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content

Partner Content
Why Join The PM Society?
Media Partner

Why Join The PM Society?

The professional organisation for people working in pharmaceutical marketing and healthcare communications, and why it's worth being part of.